Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CellSource Co., Ltd. ( (JP:4880) ) has shared an announcement.
CellSource Co., Ltd. reported a decrease in its July 2025 contract processing orders, with a significant drop in blood-derived product orders for hybrid orthopedics. Despite the decline, the company remains committed to strengthening its organizational structure and maintaining planned order volumes, while continuing initiatives with key medical institutions.
The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the biotechnology industry, focusing on contract processing services for blood-derived and adipose-derived stem cell products. The company is listed on the Tokyo Stock Exchange and targets the medical sector, including orthopedics and cosmetics.
Average Trading Volume: 50,130
Technical Sentiment Signal: Sell
Current Market Cap: Yen13.61B
For detailed information about 4880 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money